author-photo

P. Herbolsheimer

AstraZeneca

18

Papers

373

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

328TiP Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.

2020 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (67)
Abstract PD5-04: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (14)
Abstract OT3-05-03: MEDIOLA: An open-label, phase I/II basket study of olaparib (PARP inhibitor) and durvalumab (anti-PD-L1 antibody)–Additional breast cancer cohorts

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study

2019 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (63)
448TiPMEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours – new ovarian cancer cohorts

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (6)
SAFE-HEaRt: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
P1.15-004 An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (11)